Pancreatic diseases (HR: 32.68;95% CI, 18.05-59.18; P< 0.001); CKD (HR: 1.70;95% CI, 1.36-2.12; P< 0.001); Patients withless than stage 2 CKD (HR: 1.91; 95% CI, 1.28-2.83; P = 0.001); ALP(HR: 1.00;95% CI, 1.00-1.01;P = 0.040); GLPA (HR: 2.67; 95% CI, 1.00-7.12; P = 0.050); alpha-glucosidase inhibitor (HR: 1.76; 95% CI, 1.16-2.65; P = 0.008). This evidence concerns the gene GAA and chronic kidney disease.